Business
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein dru
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_O68YKj8eCWCeSjo6zZBpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":282,"olType":false},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, M.D., a globally renowned expert in the field of nuclear medicine with more than two decades of experience.","length":524,"tagName":"p"},{"type":"text","content":""Molecular Partners’ Radio-DARPins have the potential to unlock targeted radiopharmaceuticals against a broad spectrum of tumor targets. These represent ideal vectors to precisely deliver potent alpha-emitting isotopes in cancer patients. In particular, I am excited by the first human images of MP0712 presented last month and look forward to phase 1 initiation. I am honored to Chair this Scientific Advisory Board and to collaborate with this esteemed group of experts, as we work to develop therapies that can redefine patient care,” said Ken Herrmann, M.D., Chair of the Molecular Partners SAB.","length":604,"tagName":"p"},{"type":"text","content":""The precision radiopharmaceuticals being developed from our Radio-DARPin platform are showing c...